» Articles » PMID: 32286310

Sex-associated Molecular Differences for Cancer Immunotherapy

Overview
Journal Nat Commun
Specialty Biology
Date 2020 Apr 15
PMID 32286310
Citations 117
Authors
Affiliations
Soon will be listed here.
Abstract

Immune checkpoint blockade therapies have extended patient survival across multiple cancer lineages, but there is a heated debate on whether cancer immunotherapy efficacy is different between male and female patients. We summarize the existing meta-analysis to show inconsistent conclusions for whether gender is associated with the immunotherapy response. We analyze molecular profiling from ICB-treated patients to identify molecular differences for immunotherapy responsiveness. We perform comprehensive analyses for patients from The Cancer Genome Atlas (TCGA) and reveal divergent patterns for sex bias in immune features across multiple cancer types. We further validate our observations in multiple independent data sets. Considering that the majority of clinical trials are in melanoma and lung cancer, meta-analyses that pool multiple cancer types have limitations to discern whether cancer immunotherapy efficacy is different between male and female patients. Future studies should include omics profiling to investigate sex-associated molecular differences in immunotherapy.

Citing Articles

Sex-specific transcriptome similarity networks elucidate comorbidity relationships.

Sanchez-Valle J, Flores-Rodero M, Costa F, Carbonell-Caballero J, Nunez-Carpintero I, Tabares-Seisdedos R bioRxiv. 2025; .

PMID: 39896586 PMC: 11785135. DOI: 10.1101/2025.01.22.634077.


Immune checkpoint inhibitors in cancer patients with autoimmune disease: Safety and efficacy.

Le J, Sun Y, Deng G, Dian Y, Xie Y, Zeng F Hum Vaccin Immunother. 2025; 21(1):2458948.

PMID: 39894761 PMC: 11792813. DOI: 10.1080/21645515.2025.2458948.


Gender disparities in clinical outcomes of urothelial carcinoma linked to X chromosome gene mutation.

Liu Z, Jin K, Xu Z, Xu J, Su X, Li B BMJ Oncol. 2025; 2(1):e000199.

PMID: 39886491 PMC: 11234999. DOI: 10.1136/bmjonc-2023-000199.


The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis.

Tian J, Zhang L, Lin F, He R, Tian W, Yan L Front Med (Lausanne). 2025; 11:1515263.

PMID: 39867925 PMC: 11759289. DOI: 10.3389/fmed.2024.1515263.


Attenuated sex-related DNA methylation differences in cancer highlight the magnitude bias mediating existing disparities.

Zhou J, Li M, Chen Y, Wang S, Wang D, Suo C Biol Sex Differ. 2024; 15(1):106.

PMID: 39716176 PMC: 11664931. DOI: 10.1186/s13293-024-00682-4.


References
1.
Desrichard A, Snyder A, Chan T . Cancer Neoantigens and Applications for Immunotherapy. Clin Cancer Res. 2015; 22(4):807-12. DOI: 10.1158/1078-0432.CCR-14-3175. View

2.
Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

3.
Fisher D, Carpenter J, Morris T, Freeman S, Tierney J . Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?. BMJ. 2017; 356:j573. PMC: 5421441. DOI: 10.1136/bmj.j573. View

4.
Rooney M, Shukla S, Wu C, Getz G, Hacohen N . Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015; 160(1-2):48-61. PMC: 4856474. DOI: 10.1016/j.cell.2014.12.033. View

5.
Conforti F, Pala L, Bagnardi V, Viale G, De Pas T, Pagan E . Sex-based differences of the tumor mutational burden and T-cell inflammation of the tumor microenvironment. Ann Oncol. 2019; 30(4):653-655. DOI: 10.1093/annonc/mdz034. View